Recruiting
Phase 1
Phase 2

JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors

Sponsor:

Jacobio Pharmaceuticals Co., Ltd.

Code:

NCT04720976

Conditions

Solid Tumor

NSCLC

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

JAB-3312

Binimetinib

Pembrolizumab

Sotorasib

Osimertinib

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information